DaVita Inc.
DaVita Inc. (DVA) Stock Competitors & Peer Comparison
See (DVA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DVA | $150.72 | -1.53% | 10.1B | 15.83 | $9.52 | N/A |
| HCA | $532.97 | +0.07% | 119.2B | 18.82 | $28.31 | +0.54% |
| THC | $227.63 | +1.29% | 20B | 14.71 | $15.48 | N/A |
| FMS | $22.79 | +0.18% | 13.1B | 11.74 | $1.94 | +3.45% |
| UHS | $192.42 | +1.01% | 12.2B | 8.33 | $23.09 | +0.41% |
| ENSG | $209.71 | +0.65% | 12.2B | 35.85 | $5.85 | +0.12% |
| SOLV | $66.76 | +0.97% | 11.6B | 7.52 | $8.88 | N/A |
| EHC | $100.37 | +0.07% | 10.1B | 18.09 | $5.55 | +0.72% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| CHE | $401.87 | +0.58% | 5.7B | 21.96 | $18.32 | +0.57% |
Stock Comparison
DVA vs HCA Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, HCA has a market cap of 119.2B. Regarding current trading prices, DVA is priced at $150.72, while HCA trades at $532.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas HCA's P/E ratio is 18.82. In terms of profitability, DVA's ROE is -1.61%, compared to HCA's ROE of -1.41%. Regarding short-term risk, DVA is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check HCA's competition here
DVA vs THC Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, THC has a market cap of 20B. Regarding current trading prices, DVA is priced at $150.72, while THC trades at $227.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas THC's P/E ratio is 14.71. In terms of profitability, DVA's ROE is -1.61%, compared to THC's ROE of +0.35%. Regarding short-term risk, DVA is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check THC's competition here
DVA vs FMS Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, FMS has a market cap of 13.1B. Regarding current trading prices, DVA is priced at $150.72, while FMS trades at $22.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas FMS's P/E ratio is 11.74. In terms of profitability, DVA's ROE is -1.61%, compared to FMS's ROE of +0.07%. Regarding short-term risk, DVA is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check FMS's competition here
DVA vs UHS Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, UHS has a market cap of 12.2B. Regarding current trading prices, DVA is priced at $150.72, while UHS trades at $192.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas UHS's P/E ratio is 8.33. In terms of profitability, DVA's ROE is -1.61%, compared to UHS's ROE of +0.21%. Regarding short-term risk, DVA is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check UHS's competition here
DVA vs ENSG Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, ENSG has a market cap of 12.2B. Regarding current trading prices, DVA is priced at $150.72, while ENSG trades at $209.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas ENSG's P/E ratio is 35.85. In terms of profitability, DVA's ROE is -1.61%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, DVA is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check ENSG's competition here
DVA vs SOLV Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, SOLV has a market cap of 11.6B. Regarding current trading prices, DVA is priced at $150.72, while SOLV trades at $66.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas SOLV's P/E ratio is 7.52. In terms of profitability, DVA's ROE is -1.61%, compared to SOLV's ROE of +0.37%. Regarding short-term risk, DVA is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check SOLV's competition here
DVA vs EHC Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, EHC has a market cap of 10.1B. Regarding current trading prices, DVA is priced at $150.72, while EHC trades at $100.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas EHC's P/E ratio is 18.09. In terms of profitability, DVA's ROE is -1.61%, compared to EHC's ROE of +0.24%. Regarding short-term risk, DVA is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check EHC's competition here
DVA vs OSH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, DVA is priced at $150.72, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas OSH's P/E ratio is -17.65. In terms of profitability, DVA's ROE is -1.61%, compared to OSH's ROE of +4.64%. Regarding short-term risk, DVA is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check OSH's competition here
DVA vs CHE Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, CHE has a market cap of 5.7B. Regarding current trading prices, DVA is priced at $150.72, while CHE trades at $401.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas CHE's P/E ratio is 21.96. In terms of profitability, DVA's ROE is -1.61%, compared to CHE's ROE of +0.24%. Regarding short-term risk, DVA is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check CHE's competition here
DVA vs LHCG Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, DVA is priced at $150.72, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas LHCG's P/E ratio is 82.83. In terms of profitability, DVA's ROE is -1.61%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, DVA is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check LHCG's competition here
DVA vs OPCH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, OPCH has a market cap of 4.6B. Regarding current trading prices, DVA is priced at $150.72, while OPCH trades at $29.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas OPCH's P/E ratio is 23.06. In terms of profitability, DVA's ROE is -1.61%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, DVA is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check OPCH's competition here
DVA vs MMED Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, MMED has a market cap of 4.4B. Regarding current trading prices, DVA is priced at $150.72, while MMED trades at $15.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas MMED's P/E ratio is -16.77. In terms of profitability, DVA's ROE is -1.61%, compared to MMED's ROE of -0.07%. Regarding short-term risk, DVA is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check MMED's competition here
DVA vs AMED Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, DVA is priced at $150.72, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AMED's P/E ratio is 39.30. In terms of profitability, DVA's ROE is -1.61%, compared to AMED's ROE of +0.13%. Regarding short-term risk, DVA is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check AMED's competition here
DVA vs BKD Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, BKD has a market cap of 3.3B. Regarding current trading prices, DVA is priced at $150.72, while BKD trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas BKD's P/E ratio is -12.46. In terms of profitability, DVA's ROE is -1.61%, compared to BKD's ROE of -5.24%. Regarding short-term risk, DVA is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check BKD's competition here
DVA vs NHC Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, NHC has a market cap of 2.5B. Regarding current trading prices, DVA is priced at $150.72, while NHC trades at $161.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas NHC's P/E ratio is 21.02. In terms of profitability, DVA's ROE is -1.61%, compared to NHC's ROE of +0.12%. Regarding short-term risk, DVA is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check NHC's competition here
DVA vs LFST Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, LFST has a market cap of 2.5B. Regarding current trading prices, DVA is priced at $150.72, while LFST trades at $6.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas LFST's P/E ratio is 316.50. In terms of profitability, DVA's ROE is -1.61%, compared to LFST's ROE of +0.01%. Regarding short-term risk, DVA is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check LFST's competition here
DVA vs ACHC Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, ACHC has a market cap of 2.2B. Regarding current trading prices, DVA is priced at $150.72, while ACHC trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas ACHC's P/E ratio is -1.93. In terms of profitability, DVA's ROE is -1.61%, compared to ACHC's ROE of -0.39%. Regarding short-term risk, DVA is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check ACHC's competition here
DVA vs SEM Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, DVA is priced at $150.72, while SEM trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas SEM's P/E ratio is 14.01. In terms of profitability, DVA's ROE is -1.61%, compared to SEM's ROE of +0.09%. Regarding short-term risk, DVA is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check SEM's competition here
DVA vs ADUS Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, ADUS has a market cap of 1.9B. Regarding current trading prices, DVA is priced at $150.72, while ADUS trades at $101.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas ADUS's P/E ratio is 19.42. In terms of profitability, DVA's ROE is -1.61%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, DVA is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check ADUS's competition here
DVA vs AMEH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, DVA is priced at $150.72, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AMEH's P/E ratio is 39.25. In terms of profitability, DVA's ROE is -1.61%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, DVA is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check AMEH's competition here
DVA vs MD Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, MD has a market cap of 1.7B. Regarding current trading prices, DVA is priced at $150.72, while MD trades at $19.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas MD's P/E ratio is 10.08. In terms of profitability, DVA's ROE is -1.61%, compared to MD's ROE of +0.20%. Regarding short-term risk, DVA is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check MD's competition here
DVA vs SGRY Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, SGRY has a market cap of 1.6B. Regarding current trading prices, DVA is priced at $150.72, while SGRY trades at $12.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas SGRY's P/E ratio is -20.30. In terms of profitability, DVA's ROE is -1.61%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, DVA is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check SGRY's competition here
DVA vs AVAH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AVAH has a market cap of 1.5B. Regarding current trading prices, DVA is priced at $150.72, while AVAH trades at $6.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AVAH's P/E ratio is 18.81. In terms of profitability, DVA's ROE is -1.61%, compared to AVAH's ROE of -1.36%. Regarding short-term risk, DVA is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check AVAH's competition here
DVA vs HCSG Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, DVA is priced at $150.72, while HCSG trades at $19.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas HCSG's P/E ratio is 24.12. In terms of profitability, DVA's ROE is -1.61%, compared to HCSG's ROE of +0.12%. Regarding short-term risk, DVA is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check HCSG's competition here
DVA vs ARDT Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, DVA is priced at $150.72, while ARDT trades at $9.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas ARDT's P/E ratio is 9.78. In terms of profitability, DVA's ROE is -1.61%, compared to ARDT's ROE of +0.10%. Regarding short-term risk, DVA is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check ARDT's competition here
DVA vs BKDT Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, DVA is priced at $150.72, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas BKDT's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, DVA is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check BKDT's competition here
DVA vs ASTH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, ASTH has a market cap of 1.2B. Regarding current trading prices, DVA is priced at $150.72, while ASTH trades at $24.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas ASTH's P/E ratio is 52.74. In terms of profitability, DVA's ROE is -1.61%, compared to ASTH's ROE of +0.03%. Regarding short-term risk, DVA is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check ASTH's competition here
DVA vs USPH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, DVA is priced at $150.72, while USPH trades at $76.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas USPH's P/E ratio is 54.17. In terms of profitability, DVA's ROE is -1.61%, compared to USPH's ROE of +0.03%. Regarding short-term risk, DVA is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check USPH's competition here
DVA vs PNTG Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, DVA is priced at $150.72, while PNTG trades at $32.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas PNTG's P/E ratio is 39.15. In terms of profitability, DVA's ROE is -1.61%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, DVA is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check PNTG's competition here
DVA vs INNV Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, INNV has a market cap of 1.1B. Regarding current trading prices, DVA is priced at $150.72, while INNV trades at $8.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas INNV's P/E ratio is 167.80. In terms of profitability, DVA's ROE is -1.61%, compared to INNV's ROE of -0.02%. Regarding short-term risk, DVA is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check INNV's competition here
DVA vs TALK Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, TALK has a market cap of 860.8M. Regarding current trading prices, DVA is priced at $150.72, while TALK trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas TALK's P/E ratio is 171.33. In terms of profitability, DVA's ROE is -1.61%, compared to TALK's ROE of +0.07%. Regarding short-term risk, DVA is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check TALK's competition here
DVA vs FSHCX Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, FSHCX has a market cap of 812.5M. Regarding current trading prices, DVA is priced at $150.72, while FSHCX trades at $96.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas FSHCX's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to FSHCX's ROE of N/A. Regarding short-term risk, DVA is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check FSHCX's competition here
DVA vs AMN Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AMN has a market cap of 730.5M. Regarding current trading prices, DVA is priced at $150.72, while AMN trades at $18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AMN's P/E ratio is -7.62. In terms of profitability, DVA's ROE is -1.61%, compared to AMN's ROE of -0.15%. Regarding short-term risk, DVA is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check AMN's competition here
DVA vs EHAB Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, EHAB has a market cap of 690.6M. Regarding current trading prices, DVA is priced at $150.72, while EHAB trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas EHAB's P/E ratio is -151.28. In terms of profitability, DVA's ROE is -1.61%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, DVA is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check EHAB's competition here
DVA vs SNDA Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, SNDA has a market cap of 659.9M. Regarding current trading prices, DVA is priced at $150.72, while SNDA trades at $35.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas SNDA's P/E ratio is -11.76. In terms of profitability, DVA's ROE is -1.61%, compared to SNDA's ROE of -0.81%. Regarding short-term risk, DVA is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check SNDA's competition here
DVA vs CMPS Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, CMPS has a market cap of 613.5M. Regarding current trading prices, DVA is priced at $150.72, while CMPS trades at $6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas CMPS's P/E ratio is -2.35. In terms of profitability, DVA's ROE is -1.61%, compared to CMPS's ROE of -1.72%. Regarding short-term risk, DVA is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check CMPS's competition here
DVA vs MCTA Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, DVA is priced at $150.72, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas MCTA's P/E ratio is 419.36. In terms of profitability, DVA's ROE is -1.61%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, DVA is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check MCTA's competition here
DVA vs CYH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, CYH has a market cap of 443.6M. Regarding current trading prices, DVA is priced at $150.72, while CYH trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas CYH's P/E ratio is 0.85. In terms of profitability, DVA's ROE is -1.61%, compared to CYH's ROE of -0.32%. Regarding short-term risk, DVA is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check CYH's competition here
DVA vs AUNA Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AUNA has a market cap of 376.7M. Regarding current trading prices, DVA is priced at $150.72, while AUNA trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AUNA's P/E ratio is 5.36. In terms of profitability, DVA's ROE is -1.61%, compared to AUNA's ROE of +0.12%. Regarding short-term risk, DVA is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check AUNA's competition here
DVA vs AONC Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AONC has a market cap of 351M. Regarding current trading prices, DVA is priced at $150.72, while AONC trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AONC's P/E ratio is -13.48. In terms of profitability, DVA's ROE is -1.61%, compared to AONC's ROE of -0.02%. Regarding short-term risk, DVA is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check AONC's competition here
DVA vs CCRN Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, CCRN has a market cap of 308.9M. Regarding current trading prices, DVA is priced at $150.72, while CCRN trades at $9.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas CCRN's P/E ratio is -3.22. In terms of profitability, DVA's ROE is -1.61%, compared to CCRN's ROE of -0.24%. Regarding short-term risk, DVA is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check CCRN's competition here
DVA vs TOI Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, TOI has a market cap of 279.4M. Regarding current trading prices, DVA is priced at $150.72, while TOI trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas TOI's P/E ratio is -4.44. In terms of profitability, DVA's ROE is -1.61%, compared to TOI's ROE of +7.60%. Regarding short-term risk, DVA is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check TOI's competition here
DVA vs AGL Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AGL has a market cap of 250.8M. Regarding current trading prices, DVA is priced at $150.72, while AGL trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AGL's P/E ratio is -0.62. In terms of profitability, DVA's ROE is -1.61%, compared to AGL's ROE of -1.17%. Regarding short-term risk, DVA is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check AGL's competition here
DVA vs CSU Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, DVA is priced at $150.72, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas CSU's P/E ratio is 0.67. In terms of profitability, DVA's ROE is -1.61%, compared to CSU's ROE of -2.10%. Regarding short-term risk, DVA is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check CSU's competition here
DVA vs JYNT Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, JYNT has a market cap of 127.6M. Regarding current trading prices, DVA is priced at $150.72, while JYNT trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas JYNT's P/E ratio is -840.00. In terms of profitability, DVA's ROE is -1.61%, compared to JYNT's ROE of +0.14%. Regarding short-term risk, DVA is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check JYNT's competition here
DVA vs NAKAW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, DVA is priced at $150.72, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas NAKAW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to NAKAW's ROE of -0.74%. Regarding short-term risk, DVA is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check NAKAW's competition here
DVA vs AIRS Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AIRS has a market cap of 115.5M. Regarding current trading prices, DVA is priced at $150.72, while AIRS trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AIRS's P/E ratio is -6.17. In terms of profitability, DVA's ROE is -1.61%, compared to AIRS's ROE of -0.22%. Regarding short-term risk, DVA is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check AIRS's competition here
DVA vs FVE Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, DVA is priced at $150.72, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas FVE's P/E ratio is -5.64. In terms of profitability, DVA's ROE is -1.61%, compared to FVE's ROE of -0.15%. Regarding short-term risk, DVA is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check FVE's competition here
DVA vs KDLYW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, DVA is priced at $150.72, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas KDLYW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to KDLYW's ROE of -0.74%. Regarding short-term risk, DVA is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check KDLYW's competition here
DVA vs BTMD Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, BTMD has a market cap of 67M. Regarding current trading prices, DVA is priced at $150.72, while BTMD trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas BTMD's P/E ratio is 1.77. In terms of profitability, DVA's ROE is -1.61%, compared to BTMD's ROE of -0.36%. Regarding short-term risk, DVA is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check BTMD's competition here
DVA vs DCGO Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, DCGO has a market cap of 64.3M. Regarding current trading prices, DVA is priced at $150.72, while DCGO trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas DCGO's P/E ratio is -1.24. In terms of profitability, DVA's ROE is -1.61%, compared to DCGO's ROE of -0.17%. Regarding short-term risk, DVA is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check DCGO's competition here
DVA vs ALR Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, DVA is priced at $150.72, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas ALR's P/E ratio is -1.11. In terms of profitability, DVA's ROE is -1.61%, compared to ALR's ROE of -0.15%. Regarding short-term risk, DVA is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check ALR's competition here
DVA vs IMAC Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, DVA is priced at $150.72, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas IMAC's P/E ratio is -2.27. In terms of profitability, DVA's ROE is -1.61%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, DVA is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check IMAC's competition here
DVA vs CCEL Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, CCEL has a market cap of 23.5M. Regarding current trading prices, DVA is priced at $150.72, while CCEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas CCEL's P/E ratio is -9.73. In terms of profitability, DVA's ROE is -1.61%, compared to CCEL's ROE of +0.15%. Regarding short-term risk, Volatility data is not available for a full comparison. DVA has daily volatility of 5.12 and CCEL has daily volatility of N/A.Check CCEL's competition here
DVA vs AIH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, DVA is priced at $150.72, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AIH's P/E ratio is -2.78. In terms of profitability, DVA's ROE is -1.61%, compared to AIH's ROE of +1.16%. Regarding short-term risk, DVA is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check AIH's competition here
DVA vs AMS Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, AMS has a market cap of 13.7M. Regarding current trading prices, DVA is priced at $150.72, while AMS trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas AMS's P/E ratio is -5.94. In terms of profitability, DVA's ROE is -1.61%, compared to AMS's ROE of -0.09%. Regarding short-term risk, DVA is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check AMS's competition here
DVA vs CANO Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, DVA is priced at $150.72, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas CANO's P/E ratio is -0.01. In terms of profitability, DVA's ROE is -1.61%, compared to CANO's ROE of -1.49%. Regarding short-term risk, DVA is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check CANO's competition here
DVA vs PIII Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, PIII has a market cap of 10.3M. Regarding current trading prices, DVA is priced at $150.72, while PIII trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas PIII's P/E ratio is -0.06. In terms of profitability, DVA's ROE is -1.61%, compared to PIII's ROE of -3.18%. Regarding short-term risk, DVA is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check PIII's competition here
DVA vs FTRP Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, DVA is priced at $150.72, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas FTRP's P/E ratio is -1.22. In terms of profitability, DVA's ROE is -1.61%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, DVA is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check FTRP's competition here
DVA vs TOIIW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, TOIIW has a market cap of 7.2M. Regarding current trading prices, DVA is priced at $150.72, while TOIIW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas TOIIW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to TOIIW's ROE of +7.60%. Regarding short-term risk, DVA is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check TOIIW's competition here
DVA vs MODV Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, DVA is priced at $150.72, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas MODV's P/E ratio is -0.03. In terms of profitability, DVA's ROE is -1.61%, compared to MODV's ROE of +1.84%. Regarding short-term risk, DVA is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check MODV's competition here
DVA vs GBNH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, DVA is priced at $150.72, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas GBNH's P/E ratio is -0.06. In terms of profitability, DVA's ROE is -1.61%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, DVA is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check GBNH's competition here
DVA vs RHE Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, DVA is priced at $150.72, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas RHE's P/E ratio is -1.79. In terms of profitability, DVA's ROE is -1.61%, compared to RHE's ROE of +0.06%. Regarding short-term risk, DVA is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check RHE's competition here
DVA vs RHE-PA Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, DVA is priced at $150.72, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, DVA's ROE is -1.61%, compared to RHE-PA's ROE of -0.04%. Regarding short-term risk, DVA is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check RHE-PA's competition here
DVA vs ATIP Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, DVA is priced at $150.72, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas ATIP's P/E ratio is -0.03. In terms of profitability, DVA's ROE is -1.61%, compared to ATIP's ROE of +0.23%. Regarding short-term risk, DVA is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check ATIP's competition here
DVA vs IMACW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, DVA is priced at $150.72, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas IMACW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, DVA is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check IMACW's competition here
DVA vs SYRA Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, SYRA has a market cap of 1.2M. Regarding current trading prices, DVA is priced at $150.72, while SYRA trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas SYRA's P/E ratio is -1.31. In terms of profitability, DVA's ROE is -1.61%, compared to SYRA's ROE of -0.55%. Regarding short-term risk, DVA is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check SYRA's competition here
DVA vs MNDR Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, MNDR has a market cap of 764.5K. Regarding current trading prices, DVA is priced at $150.72, while MNDR trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas MNDR's P/E ratio is -0.05. In terms of profitability, DVA's ROE is -1.61%, compared to MNDR's ROE of -1.29%. Regarding short-term risk, DVA is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check MNDR's competition here
DVA vs TALKW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, TALKW has a market cap of 646.1K. Regarding current trading prices, DVA is priced at $150.72, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas TALKW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, DVA is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check TALKW's competition here
DVA vs CCM Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, CCM has a market cap of 541.7K. Regarding current trading prices, DVA is priced at $150.72, while CCM trades at $3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas CCM's P/E ratio is -0.69. In terms of profitability, DVA's ROE is -1.61%, compared to CCM's ROE of +0.07%. Regarding short-term risk, DVA is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check CCM's competition here
DVA vs BACK Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, BACK has a market cap of 212.7K. Regarding current trading prices, DVA is priced at $150.72, while BACK trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas BACK's P/E ratio is -0.02. In terms of profitability, DVA's ROE is -1.61%, compared to BACK's ROE of +1.05%. Regarding short-term risk, Volatility data is not available for a full comparison. DVA has daily volatility of 5.12 and BACK has daily volatility of N/A.Check BACK's competition here
DVA vs NVOS Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, NVOS has a market cap of 61.2K. Regarding current trading prices, DVA is priced at $150.72, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas NVOS's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, DVA is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check NVOS's competition here
DVA vs NIVFW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, NIVFW has a market cap of 37.7K. Regarding current trading prices, DVA is priced at $150.72, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas NIVFW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to NIVFW's ROE of +1.17%. Regarding short-term risk, DVA is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check NIVFW's competition here
DVA vs PIIIW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, PIIIW has a market cap of 21.5K. Regarding current trading prices, DVA is priced at $150.72, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas PIIIW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to PIIIW's ROE of -3.18%. Regarding short-term risk, DVA is more volatile compared to PIIIW. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check PIIIW's competition here
DVA vs IONM Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, DVA is priced at $150.72, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas IONM's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to IONM's ROE of +5.28%. Regarding short-term risk, DVA is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check IONM's competition here
DVA vs DVCR Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas DVCR's P/E ratio is 28.34. In terms of profitability, DVA's ROE is -1.61%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, DVA is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check DVCR's competition here
DVA vs TVTY Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas TVTY's P/E ratio is 19.06. In terms of profitability, DVA's ROE is -1.61%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, DVA is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check TVTY's competition here
DVA vs NFH Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, NFH has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas NFH's P/E ratio is -19.75. In terms of profitability, DVA's ROE is -1.61%, compared to NFH's ROE of -0.06%. Regarding short-term risk, DVA is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check NFH's competition here
DVA vs TLMD Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas TLMD's P/E ratio is -1.60. In terms of profitability, DVA's ROE is -1.61%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, DVA is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check TLMD's competition here
DVA vs TLMDW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas TLMDW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, DVA is more volatile compared to TLMDW. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check TLMDW's competition here
DVA vs HNGR Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas HNGR's P/E ratio is 19.71. In terms of profitability, DVA's ROE is -1.61%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, DVA is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check HNGR's competition here
DVA vs SLHG Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas SLHG's P/E ratio is -1.48. In terms of profitability, DVA's ROE is -1.61%, compared to SLHG's ROE of N/A. Regarding short-term risk, DVA is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check SLHG's competition here
DVA vs DCGOW Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas DCGOW's P/E ratio is N/A. In terms of profitability, DVA's ROE is -1.61%, compared to DCGOW's ROE of -0.17%. Regarding short-term risk, DVA is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for DVA.Check DCGOW's competition here
DVA vs SLHGP Comparison March 2026
DVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DVA stands at 10.1B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, DVA is priced at $150.72, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DVA currently has a P/E ratio of 15.83, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, DVA's ROE is -1.61%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, DVA is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for DVA.Check SLHGP's competition here